×
English
हिंदी
ગુજરાતી
Home
My Feed
Remove Ads
Get Premium Content
Go Pro @₹99
Credit Cards
Instant Loans
Apply Now
Credit Score
Refer & Earn ₹500
Refer Now
Finance Tracker
Learning Curve
Fixed Deposits
Business Loan
Vouchers
Markets
Markets
FII & DII Activity
Corporate Action
Research Advice
Earnings
Technical Trends
Stock Deals
Intraday Large Deals
Bonds
Webinar
Pre Market
Stock Scanner
Sector Analysis
Unlisted Shares
Stock Updates
PRO Stock Lists
Monsoon Tracker
Seasonality Analysis
Crypto Dashboard
Web Stories
Tax Calculator
Forum
Gold Rate
Silver Rate
IFSC Code Finder
Storyboard18
IPO
Economic Indicators
Economic Calendar
Global Markets
US Markets
ETFs
Indian Indices
News
News
Tech/Startups
Auto
Research
Opinion
Politics
Personal Finance
EPF Guide
Real Estate
Portfolio
Watchlist
Personal Finance
Personal Finance
Loans
Fixed Deposit Comparison
Fixed Deposit Interest Calculator
Moneycontrol - SecureNow Health Insurance ratings
Mutual Funds
Mutual Funds
Performance Tracker
Top ranked funds
My Portfolio
Top performing Categories
Forum
New Fund Offers
MF Simplified
Commodities
Mutual Funds
Gold Rate
Silver Rate
Currencies
Cryptocurrency
Media
Live TV & Shows
Video
Podcast
Photos
Invest Now
Trade like Experts
Invest in Unlisted Shares
Specials
Pharma Industry Conclave
Unlocking opportunities in Metal and Mining
#MFSummit2025
Moneycontrol mutual fund summit 2025
Advanced Technical Charts
International
Get App
Be a
Pro
Home
PRO
Markets
News
Editor’s Picks
Tech
India
Learning Curve
Portfolio
Watchlist
Commodities
MF
Personal Finance
Forum
Videos
you are here:
Home
News
Generics
Generics
Fresh Trump tariffs, what is at stake for Indian pharma, and the playbook to survive
IPA rejects Ohio University study linking higher adverse events to made in India generics
Indian drugmakers weigh portfolio rejig, manufacturing realignment to survive US tariffs
Hetero finds positive results from Molnupiravir third phase trials
Veterans Unpacked | D.S. Brar: "Your network is your net worth, and your credibility is your currency"
Corporate Corridor | Pfizer’s Upjohn and Mylan combining forces holds lessons for Indian pharma majors
Dr Reddy’s Suboxone launch: Why investors shrugged it off
Why Scott Gottlieb, the new US FDA chief, could be good news for Indian drug makers
Pharma stocks gain post Clinton's loss: Sun, Dr Reddy‘s up 5%
EY Passion to Win: Here's the success story of the Lupin duo
US-led trade deal will raise prices: Indian drug industry
Lupin to beef up branded portfolio through alliances
Lupin falls 6%, analysts revise target post weak Q4 results
3 reasons why BofA-Merrill is still hot on Cipla
Lupin scouts for acquisitions in US
Why action is unlikely in US generics pricing probe
US drug patent expiries to benefit Indian pharma industry
USFDA nod will aid Ranbaxy's sentiment, not revenue: Expert
Swedish drugmaker Meda says not in sale talks
Dr Reddy's Q4 cons net jumps 67% to Rs 571 cr
Ranbaxy misses estimates; Q1 net sinks 90%
Glenmark: Environment challenging, see 20% growth in FY14
Glenmark settles patent litigation with Janssen Pharma
Glenmark, Aurobindo get US nod for asthma treatment drug
Growth in quarter driven by generics: Lupin
View More
Home
Markets
Loans
SPIN
2
WIN
News
Portfolio